The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless hype ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Novo and Lilly are also working on oral weight loss drugs ... has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...